Cargando…

Induction of labour versus expectant management in women with preterm prelabour rupture of membranes between 34 and 37 weeks (the PPROMEXIL-trial)

BACKGROUND: Preterm prelabour rupture of the membranes (PPROM) is an important clinical problem and a dilemma for the gynaecologist. On the one hand, awaiting spontaneous labour increases the probability of infectious disease for both mother and child, whereas on the other hand induction of labour l...

Descripción completa

Detalles Bibliográficos
Autores principales: van der Ham, David P, Nijhuis, Jan G, Mol, Ben Willem J, van Beek, Johannes J, Opmeer, Brent C, Bijlenga, Denise, Groenewout, Mariette, Arabin, Birgit, Bloemenkamp, Kitty WM, van Wijngaarden, Wim J, Wouters, Maurice GAJ, Pernet, Paula JM, Porath, Martina M, Molkenboer, Jan FM, Derks, Jan B, Kars, Michael M, Scheepers, Hubertina CJ, Weinans, Martin JN, Woiski, Mallory D, Wildschut, Hajo IJ, Willekes, Christine
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2007
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1934382/
https://www.ncbi.nlm.nih.gov/pubmed/17617892
http://dx.doi.org/10.1186/1471-2393-7-11
_version_ 1782134347986370560
author van der Ham, David P
Nijhuis, Jan G
Mol, Ben Willem J
van Beek, Johannes J
Opmeer, Brent C
Bijlenga, Denise
Groenewout, Mariette
Arabin, Birgit
Bloemenkamp, Kitty WM
van Wijngaarden, Wim J
Wouters, Maurice GAJ
Pernet, Paula JM
Porath, Martina M
Molkenboer, Jan FM
Derks, Jan B
Kars, Michael M
Scheepers, Hubertina CJ
Weinans, Martin JN
Woiski, Mallory D
Wildschut, Hajo IJ
Willekes, Christine
author_facet van der Ham, David P
Nijhuis, Jan G
Mol, Ben Willem J
van Beek, Johannes J
Opmeer, Brent C
Bijlenga, Denise
Groenewout, Mariette
Arabin, Birgit
Bloemenkamp, Kitty WM
van Wijngaarden, Wim J
Wouters, Maurice GAJ
Pernet, Paula JM
Porath, Martina M
Molkenboer, Jan FM
Derks, Jan B
Kars, Michael M
Scheepers, Hubertina CJ
Weinans, Martin JN
Woiski, Mallory D
Wildschut, Hajo IJ
Willekes, Christine
author_sort van der Ham, David P
collection PubMed
description BACKGROUND: Preterm prelabour rupture of the membranes (PPROM) is an important clinical problem and a dilemma for the gynaecologist. On the one hand, awaiting spontaneous labour increases the probability of infectious disease for both mother and child, whereas on the other hand induction of labour leads to preterm birth with an increase in neonatal morbidity (e.g., respiratory distress syndrome (RDS)) and a possible rise in the number of instrumental deliveries. METHODS/DESIGN: We aim to determine the effectiveness and cost-effectiveness of immediate delivery after PPROM in near term gestation compared to expectant management. Pregnant women with preterm prelabour rupture of the membranes at a gestational age from 34(+0 )weeks until 37(+0 )weeks will be included in a multicentre prospective randomised controlled trial. We will compare early delivery with expectant monitoring. The primary outcome of this study is neonatal sepsis. Secondary outcome measures are maternal morbidity (chorioamnionitis, puerperal sepsis) and neonatal disease, instrumental delivery rate, maternal quality of life, maternal preferences and costs. We anticipate that a reduction of neonatal infection from 7.5% to 2.5% after induction will outweigh an increase in RDS and additional costs due to admission of the child due to prematurity. Under these assumptions, we aim to randomly allocate 520 women to two groups of 260 women each. Analysis will be by intention to treat. Additionally a cost-effectiveness analysis will be performed to evaluate if the cost related to early delivery will outweigh those of expectant management. Long term outcomes will be evaluated using modelling. DISCUSSION: This trial will provide evidence as to whether induction of labour after preterm prelabour rupture of membranes is an effective and cost-effective strategy to reduce the risk of neonatal sepsis. CONTROLLED CLINICAL TRIAL REGISTER: ISRCTN29313500
format Text
id pubmed-1934382
institution National Center for Biotechnology Information
language English
publishDate 2007
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-19343822007-07-28 Induction of labour versus expectant management in women with preterm prelabour rupture of membranes between 34 and 37 weeks (the PPROMEXIL-trial) van der Ham, David P Nijhuis, Jan G Mol, Ben Willem J van Beek, Johannes J Opmeer, Brent C Bijlenga, Denise Groenewout, Mariette Arabin, Birgit Bloemenkamp, Kitty WM van Wijngaarden, Wim J Wouters, Maurice GAJ Pernet, Paula JM Porath, Martina M Molkenboer, Jan FM Derks, Jan B Kars, Michael M Scheepers, Hubertina CJ Weinans, Martin JN Woiski, Mallory D Wildschut, Hajo IJ Willekes, Christine BMC Pregnancy Childbirth Study Protocol BACKGROUND: Preterm prelabour rupture of the membranes (PPROM) is an important clinical problem and a dilemma for the gynaecologist. On the one hand, awaiting spontaneous labour increases the probability of infectious disease for both mother and child, whereas on the other hand induction of labour leads to preterm birth with an increase in neonatal morbidity (e.g., respiratory distress syndrome (RDS)) and a possible rise in the number of instrumental deliveries. METHODS/DESIGN: We aim to determine the effectiveness and cost-effectiveness of immediate delivery after PPROM in near term gestation compared to expectant management. Pregnant women with preterm prelabour rupture of the membranes at a gestational age from 34(+0 )weeks until 37(+0 )weeks will be included in a multicentre prospective randomised controlled trial. We will compare early delivery with expectant monitoring. The primary outcome of this study is neonatal sepsis. Secondary outcome measures are maternal morbidity (chorioamnionitis, puerperal sepsis) and neonatal disease, instrumental delivery rate, maternal quality of life, maternal preferences and costs. We anticipate that a reduction of neonatal infection from 7.5% to 2.5% after induction will outweigh an increase in RDS and additional costs due to admission of the child due to prematurity. Under these assumptions, we aim to randomly allocate 520 women to two groups of 260 women each. Analysis will be by intention to treat. Additionally a cost-effectiveness analysis will be performed to evaluate if the cost related to early delivery will outweigh those of expectant management. Long term outcomes will be evaluated using modelling. DISCUSSION: This trial will provide evidence as to whether induction of labour after preterm prelabour rupture of membranes is an effective and cost-effective strategy to reduce the risk of neonatal sepsis. CONTROLLED CLINICAL TRIAL REGISTER: ISRCTN29313500 BioMed Central 2007-07-06 /pmc/articles/PMC1934382/ /pubmed/17617892 http://dx.doi.org/10.1186/1471-2393-7-11 Text en Copyright © 2007 van der Ham et al; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License ( (http://creativecommons.org/licenses/by/2.0) ), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Study Protocol
van der Ham, David P
Nijhuis, Jan G
Mol, Ben Willem J
van Beek, Johannes J
Opmeer, Brent C
Bijlenga, Denise
Groenewout, Mariette
Arabin, Birgit
Bloemenkamp, Kitty WM
van Wijngaarden, Wim J
Wouters, Maurice GAJ
Pernet, Paula JM
Porath, Martina M
Molkenboer, Jan FM
Derks, Jan B
Kars, Michael M
Scheepers, Hubertina CJ
Weinans, Martin JN
Woiski, Mallory D
Wildschut, Hajo IJ
Willekes, Christine
Induction of labour versus expectant management in women with preterm prelabour rupture of membranes between 34 and 37 weeks (the PPROMEXIL-trial)
title Induction of labour versus expectant management in women with preterm prelabour rupture of membranes between 34 and 37 weeks (the PPROMEXIL-trial)
title_full Induction of labour versus expectant management in women with preterm prelabour rupture of membranes between 34 and 37 weeks (the PPROMEXIL-trial)
title_fullStr Induction of labour versus expectant management in women with preterm prelabour rupture of membranes between 34 and 37 weeks (the PPROMEXIL-trial)
title_full_unstemmed Induction of labour versus expectant management in women with preterm prelabour rupture of membranes between 34 and 37 weeks (the PPROMEXIL-trial)
title_short Induction of labour versus expectant management in women with preterm prelabour rupture of membranes between 34 and 37 weeks (the PPROMEXIL-trial)
title_sort induction of labour versus expectant management in women with preterm prelabour rupture of membranes between 34 and 37 weeks (the ppromexil-trial)
topic Study Protocol
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1934382/
https://www.ncbi.nlm.nih.gov/pubmed/17617892
http://dx.doi.org/10.1186/1471-2393-7-11
work_keys_str_mv AT vanderhamdavidp inductionoflabourversusexpectantmanagementinwomenwithpretermprelabourruptureofmembranesbetween34and37weekstheppromexiltrial
AT nijhuisjang inductionoflabourversusexpectantmanagementinwomenwithpretermprelabourruptureofmembranesbetween34and37weekstheppromexiltrial
AT molbenwillemj inductionoflabourversusexpectantmanagementinwomenwithpretermprelabourruptureofmembranesbetween34and37weekstheppromexiltrial
AT vanbeekjohannesj inductionoflabourversusexpectantmanagementinwomenwithpretermprelabourruptureofmembranesbetween34and37weekstheppromexiltrial
AT opmeerbrentc inductionoflabourversusexpectantmanagementinwomenwithpretermprelabourruptureofmembranesbetween34and37weekstheppromexiltrial
AT bijlengadenise inductionoflabourversusexpectantmanagementinwomenwithpretermprelabourruptureofmembranesbetween34and37weekstheppromexiltrial
AT groenewoutmariette inductionoflabourversusexpectantmanagementinwomenwithpretermprelabourruptureofmembranesbetween34and37weekstheppromexiltrial
AT arabinbirgit inductionoflabourversusexpectantmanagementinwomenwithpretermprelabourruptureofmembranesbetween34and37weekstheppromexiltrial
AT bloemenkampkittywm inductionoflabourversusexpectantmanagementinwomenwithpretermprelabourruptureofmembranesbetween34and37weekstheppromexiltrial
AT vanwijngaardenwimj inductionoflabourversusexpectantmanagementinwomenwithpretermprelabourruptureofmembranesbetween34and37weekstheppromexiltrial
AT woutersmauricegaj inductionoflabourversusexpectantmanagementinwomenwithpretermprelabourruptureofmembranesbetween34and37weekstheppromexiltrial
AT pernetpaulajm inductionoflabourversusexpectantmanagementinwomenwithpretermprelabourruptureofmembranesbetween34and37weekstheppromexiltrial
AT porathmartinam inductionoflabourversusexpectantmanagementinwomenwithpretermprelabourruptureofmembranesbetween34and37weekstheppromexiltrial
AT molkenboerjanfm inductionoflabourversusexpectantmanagementinwomenwithpretermprelabourruptureofmembranesbetween34and37weekstheppromexiltrial
AT derksjanb inductionoflabourversusexpectantmanagementinwomenwithpretermprelabourruptureofmembranesbetween34and37weekstheppromexiltrial
AT karsmichaelm inductionoflabourversusexpectantmanagementinwomenwithpretermprelabourruptureofmembranesbetween34and37weekstheppromexiltrial
AT scheepershubertinacj inductionoflabourversusexpectantmanagementinwomenwithpretermprelabourruptureofmembranesbetween34and37weekstheppromexiltrial
AT weinansmartinjn inductionoflabourversusexpectantmanagementinwomenwithpretermprelabourruptureofmembranesbetween34and37weekstheppromexiltrial
AT woiskimalloryd inductionoflabourversusexpectantmanagementinwomenwithpretermprelabourruptureofmembranesbetween34and37weekstheppromexiltrial
AT wildschuthajoij inductionoflabourversusexpectantmanagementinwomenwithpretermprelabourruptureofmembranesbetween34and37weekstheppromexiltrial
AT willekeschristine inductionoflabourversusexpectantmanagementinwomenwithpretermprelabourruptureofmembranesbetween34and37weekstheppromexiltrial